血清肿瘤标志物联合检测在卵巢癌早期诊断中的临床价值研究

Clinical value research of serum tumor markers in the early diagnosis of ovarian cancer

目的探讨联合检测溶血磷脂酸(LPA)、恶性肿瘤特异性生长因子(TSGF)、糖类抗原125(CA125)在早期卵巢癌早期诊断中的价值和意义。方法按照随机数字表的方法选取124例于2014年2月至2016年1月间就诊的卵巢癌患者作为研究对象并设为卵巢癌组,同样按照随机数字表的方法选取于2014年2月至2016年1月间来我院就诊的42例卵巢良性肿瘤以及50例健康体检女性患者作为研究对象并分别设为卵巢良性肿瘤组和正常对照组,分别检测三组患者的血清LPA、TSGF和CA125,进行统计学分析并判断联合检测三种血清肿瘤标志物在临床应用价值。结果卵巢癌组患者血清LPA、TSGF、CA125水平明显高于卵巢良性肿瘤组和正常对照组,卵巢良性肿瘤组血清LPA、TSGF、CA125水平明显高于正常对照组,差异均有统计学意义(P<0.05)。LPA、TSGF、CA125联合检测其灵敏度、特异度较单一检测、两两检测相比均显著升高。结论卵巢癌早期患者在诊疗过程中联合检测LPA、TSGF、CA125三者水平,能够提高临床检测的灵敏度和特异度,有助于临床早期发现病情并实施有效的治疗手段。

Objective To analyze and research the value and significance of lysophospholipids acid （ LPA） , malignant tumor specific growth factor （TSGF） , carbohydrate antigen 125 （CA125） joint detection in the process of diagnosis and treatment, in order to improve clinical diagnosis rate of early ovarian cancer and reduce missed diagnosis and misdiagnosis rate. Methods 124 cases with ovarian cancer, which admitted in our hospital during February 2014 - January 2016, were selected as the research object according to the random number table method and set as the experimental group. At the same time between February 2014 to January 2016,42 cases of benign ovarian tumor and 50 cases of healthy check - up female patients in our hospital were set as the control group and normal group respectively, according to random number table method. The LPA, TSGF, CA125 of the three groups were detected and were given the statistical analysis. The clinical application value of three serum tumor markers joint detection was determined. Results The serum levels of LPA, TSGF, CA125 of ovarian cancer group were significantly higher than those of ovarian benign tumor group and normal control group （ P 〈 0. 05）. The LPA, TSGF, CA125 of ovarian benign tumor group were sig-nificantly higher than those of normal control group （ P 〈 0 . 05）. The LPA, TSGF, CA12 5 united detection sensitivity, specific degrees compared with single detection, the double detection were significantly increased, the difference was significant statistically significant （ P 〈 0 . 0 5 ） . Conclusion The combined detection of LPA and TSGF, CA125 levels in the process of early diagnosis and treatment for patients with ovarian cancer not only can enhance the accuracy in clinical testing, but also can guide clinicians to make correct treatment, reduce the incidence of adverse e-vents, which is worthy of clinical popularization and application.